In cases of acute chest pain, which treatment should not be used in pregnant patients?

In the context of treating acute chest pain in pregnant patients, the use of angiotensin-converting enzyme (ACE) inhibitors is contraindicated due to their potential teratogenic effects. ACE inhibitors have been associated with significant fetal risks, particularly during the second and third trimesters, where they can lead to adverse outcomes such as fetal renal dysfunction, oligohydramnios, and skull hypoplasia.

In contrast, beta-blockers, calcium channel blockers, and nitrates can be used in carefully monitored situations during pregnancy, as they are generally considered safer options. Beta-blockers may be indicated for certain types of cardiac conditions, while calcium channel blockers can help manage hypertension. Nitrates are also commonly used to relieve angina and improve blood flow, with careful monitoring to avoid hypotension.

Therefore, ACE inhibitors stand out as the treatment option that should not be utilized in pregnant patients when addressing acute chest pain.